Edition:
United States

U.S. FDA Files NDA Under Priority Review For Migalastat


Monday, 12 Feb 2018 07:30am EST 

Feb 12 (Reuters) - Amicus Therapeutics Inc ::U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE.AMICUS THERAPEUTICS INC - PRESCRIPTION DRUG USER FEE ACT GOAL DATE FOR FDA DECISION IS AUGUST 13, 2018.